for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NuVasive, Inc.

NUVA.OQ

Latest Trade

66.72USD

Change

1.64(+2.52%)

Volume

434,015

Today's Range

65.48

 - 

67.16

52 Week Range

43.52

 - 

72.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
65.08
Open
65.67
Volume
434,015
3M AVG Volume
8.82
Today's High
67.16
Today's Low
65.48
52 Week High
72.38
52 Week Low
43.52
Shares Out (MIL)
52.05
Market Cap (MIL)
3,472.51
Forward P/E
28.75
Dividend (Yield %)
--

Next Event

Q3 2019 NuVasive Inc Earnings Release

Latest Developments

More

Alphatec Announces Favorable Judgment In Nuvasive V. Miles Lawsuit

Nuvasive Q2 GAAP Earnings Per Share $0.29

NuVasive Says Its SpineTRACK Registry Meets 2018 Medicare Reporting Requirements

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NuVasive, Inc.

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Industry

Medical Equipment & Supplies

Contact Info

7475 Lusk Blvd

+1.858.9091800

http://www.nuvasive.com

Executive Leadership

Gregory T. Lucier

Chairman of the Board

J. Christopher Barry

Chief Executive Officer, Director

Rajesh J. Asarpota

Principal Financial Officer, Executive Vice President, Principal Accounting Officer

Paul McClintock

President - U.S. Commercial

Lucas Vitale

Chief Human Resource Officer

Key Stats

2.67 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.0K

2017

1.0K

2018

1.1K

2019(E)

1.2K
EPS (USD)

2016

1.660

2017

1.910

2018

2.230

2019(E)

2.321
Price To Earnings (TTM)
67.07
Price To Sales (TTM)
3.08
Price To Book (MRQ)
4.02
Price To Cash Flow (TTM)
18.70
Total Debt To Equity (MRQ)
71.09
LT Debt To Equity (MRQ)
71.09
Return on Investment (TTM)
3.39
Return on Equity (TTM)
3.02

Latest News

Smith & Nephew in talks to buy NuVasive for over $3 billion: FT

Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

UPDATE 1-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

BRIEF-NuVasive Reports Q1 GAAP Loss Per Share Of $0.53

* FY2018 REVENUE VIEW $1.10 BILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Nuvasive Posts Q4 Adj. Earnings Per Share $0.56

* NUVASIVE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-John DeFord To Join NuVasive Board Of Directors

* NUVASIVE INC - AS A RESULT OF DEFORD'S APPOINTMENT, NUVASIVE BOARD OF DIRECTORS CONSISTS OF 10 DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-NuVasive Comments On Expected Impact Of U.S. Tax Reform

* NUVASIVE INC - SAVINGS FROM TAX REFORM EXPECTED TO BOOST FORWARD-LOOKING FREE CASH FLOW, NON-GAAP EPS IN EXCESS OF 10 % PER YEAR BEGINNING IN 2018

BRIEF-Nuvasive To Acquire Safepassage

* NUVASIVE INC - NUVASIVE EXPECTS TRANSACTION TO BE ACCRETIVE TO COMPANY'S NON-GAAP EARNINGS PER SHARE (EPS) IN 2018 AND BEYOND

BRIEF-NuVasive Inc reports Q3 GAAP earnings per share $0.64

* NuVasive Inc sees revenue and non-GAAP revenue of $1,030 million for fy 2017

BRIEF-NuVasive announces $100 million share repurchase program

* NuVasive Inc - intends to fund repurchases under share repurchase program from cash on hand, cash generated from operations

BRIEF-NuVasive receives expanded FDA 510(k) clearance For TLX Interbody System used in TLIF procedures

* NuVasive receives expanded FDA 510(k) clearance For TLX Interbody System used in TLIF procedures

BRIEF-NuVasive receives expanded FDA 510(k) clearance for innovative magnetic limb lengthening technology

* NuVasive receives expanded FDA 510(k) clearance for innovative magnetic limb lengthening technology

NuVasive sues former executive who moved to rival Alphatec

NuVasive Inc on Tuesday filed a lawsuit accusing a former executive and director of discouraging the company from buying rival medical device maker Alphatec Holdings Inc so he could invest in Alphatec himself, and ultimately become its executive chairman.

BRIEF-NuVasive files lawsuit against Patrick S. Miles

* Nuvasive files lawsuit against patrick s. Miles to protect corporate assets and stakeholders' interests

BRIEF-NuVasive says ‍commercial launch of its lessray software technology system​

* Nuvasive Inc - commercial launch of its Lessray Software technology system Source text for Eikon: Further company coverage:

BRIEF-Nuvasive buys privately-held medical device co Vertera Spine

* Announced acquisition of Vertera Spine, a privately-held medical device company

BRIEF-Nuvasive receives FDA 510(K) clearance for leading EOS innovation

* Nuvasive receives FDA 510(K) clearance for leading EOS innovation Source text for Eikon: Further company coverage:

BRIEF-NuVasive appoints Rajesh Asarpota as CFO

* NuVasive appoints Rajesh Asarpota as chief financial officer, effective September 1, 2017 Source text for Eikon: Further company coverage:

BRIEF-Nuvasive announces new organizational structure

* Nuvasive Inc says it has accepted resignation of its CFO Quentin Blackford, effective August 25, 2017

BRIEF-Nuvasive Q2 earnings per share $0.22

* Says company reiterates revenue, non-gaap operating margin and non-gaap diluted earnings per share guidance for 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up